ASCO Accepts Three Abstracts on the ChemoFx® Drug Response Marker
The American Society of Clinical Oncology (ASCO) has accepted three individual abstracts that highlight the utility and feasibility of Precision Therapeutics‘s ChemoFx® Drug Response Marker for patients with gynecologic sarcomas, cervical cancer and ovarian cancer. These abstracts will be published in conjunction with ASCO’s 2012 Annual Symposium, being held June 1-5, 2012 in Chicago, Illinois.
The first abstract, titled, In Vitro Chemosensitivity Assay for Patients with Gynecologic Sarcoma, demonstrates whether ChemoFx can be used to help determine treatment decisions for patients with gynecologic sarcomas. Another abstract, titled, In Vitro Chemoresponse Assay for Patients with Cervical Cancer, shares the results of ChemoFx testing in primary, metastatic and recurrent cervical cancer. The third abstract titled, In Vitro Chemoresponse Assay Results and Population Clinical Response Rates in Women with Ovarian Cancer, determines whether in vitro platinum sensitivity rates are similar to published population response rates for ovarian cancer and examines differences in platinum sensitivity across histologic subtypes.
“We are very pleased with the outcomes to date from these three studies,” says Dr. Karl Williams, Chief Medical Director for Precision Therapeutics, Inc. “We look forward to watching these projects progress and further analyzing the value of ChemoFx for these difficult to treat patients.” Learn more at www.precisiontherapeutics.com.